{"transactions":[{"id":779143,"issuer":{"id":6092,"kind":"organization","name":"Surrozen, Inc./DE"},"owners":[{"id":47341,"kind":"person","name":"WOODHOUSE DAVID J","position":1,"cik":"0001642995","reported_name":"WOODHOUSE DAVID J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2026-05-14T20:51:04.000Z","date":"2026-05-13","kind":"grant","planned":false,"acquired":true,"shares":5550,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest and become exercisable on the anniversary of the grant date, subject to continuous service as a director."}],"balance_after":5550,"derivative":{"exercise_price":30.14,"exercise_date":"2027-05-13","expiration_date":"2036-05-12","underlying":"Common Stock","underlying_shares":5550},"source":{"system":"sec-edgar","filing":"0001193125-26-224244","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1642995/000119312526224244/ownership.xml","form_type":"4"}},{"id":1147308,"issuer":{"id":6092,"kind":"organization","name":"Surrozen, Inc./DE"},"owners":[{"id":47341,"kind":"person","name":"WOODHOUSE DAVID J","position":1,"cik":"0001642995","reported_name":"WOODHOUSE DAVID J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2025-05-15T21:16:07.000Z","date":"2025-05-14","kind":"grant","planned":false,"acquired":true,"shares":1333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest and become exercisable on the anniversary of the grant date, subject to continuous service as a director."}],"balance_after":1333,"derivative":{"exercise_price":6.5,"exercise_date":"2026-05-14","expiration_date":"2035-05-14","underlying":"Common Stock","underlying_shares":1333},"source":{"system":"sec-edgar","filing":"0001593968-25-000608","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1642995/000159396825000608/primary_01.xml","form_type":"4"}},{"id":1488392,"issuer":{"id":6092,"kind":"organization","name":"Surrozen, Inc./DE"},"owners":[{"id":47341,"kind":"person","name":"WOODHOUSE DAVID J","position":1,"cik":"0001642995","reported_name":"WOODHOUSE DAVID J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2024-06-07T00:34:59.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":1333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest and become exercisable on the anniversary of the grant date, subject to continuous service as a director."}],"balance_after":1333,"derivative":{"exercise_price":11,"exercise_date":"2025-06-05","expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":1333},"source":{"system":"sec-edgar","filing":"0001593968-24-000834","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1642995/000159396824000834/primary_01.xml","form_type":"4"}},{"id":1545629,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":47341,"kind":"person","name":"WOODHOUSE DAVID J","position":1,"cik":"0001642995","reported_name":"WOODHOUSE DAVID J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-04-08T20:14:24.000Z","date":"2024-04-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":500000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. (\"Parent\") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent (\"Purchaser\"), dated as of February 25, 2024 (\"Merger Agreement\"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the \"Effective Time\"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the \"Offer Price\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an \"In-the-Money Option\") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. (\"Parent\") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent (\"Purchaser\"), dated as of February 25, 2024 (\"Merger Agreement\"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the \"Effective Time\"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the \"Offer Price\")."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an \"In-the-Money Option\") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an \"In-the-Money Option\") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration."}],"balance_after":0,"derivative":{"exercise_price":4.36,"expiration_date":"2033-03-01","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0000950170-24-042609","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1642995/000095017024042609/ownership.xml","form_type":"4"}},{"id":1545628,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":47341,"kind":"person","name":"WOODHOUSE DAVID J","position":1,"cik":"0001642995","reported_name":"WOODHOUSE DAVID J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-04-08T20:14:24.000Z","date":"2024-04-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":381600,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. (\"Parent\") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent (\"Purchaser\"), dated as of February 25, 2024 (\"Merger Agreement\"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the \"Effective Time\"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the \"Offer Price\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an \"In-the-Money Option\") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. (\"Parent\") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent (\"Purchaser\"), dated as of February 25, 2024 (\"Merger Agreement\"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the \"Effective Time\"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the \"Offer Price\")."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an \"In-the-Money Option\") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an \"In-the-Money Option\") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration."}],"balance_after":0,"derivative":{"exercise_price":4.36,"expiration_date":"2033-03-01","underlying":"Common Stock","underlying_shares":381600},"source":{"system":"sec-edgar","filing":"0000950170-24-042609","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1642995/000095017024042609/ownership.xml","form_type":"4"}},{"id":1545627,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":47341,"kind":"person","name":"WOODHOUSE DAVID J","position":1,"cik":"0001642995","reported_name":"WOODHOUSE DAVID J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-04-08T20:14:24.000Z","date":"2024-04-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":500000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. (\"Parent\") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent (\"Purchaser\"), dated as of February 25, 2024 (\"Merger Agreement\"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the \"Effective Time\"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the \"Offer Price\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an \"In-the-Money Option\") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. (\"Parent\") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent (\"Purchaser\"), dated as of February 25, 2024 (\"Merger Agreement\"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the \"Effective Time\"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the \"Offer Price\")."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an \"In-the-Money Option\") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an \"In-the-Money Option\") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration."}],"balance_after":0,"derivative":{"exercise_price":0.84,"expiration_date":"2032-03-02","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0000950170-24-042609","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1642995/000095017024042609/ownership.xml","form_type":"4"}},{"id":1545626,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":47341,"kind":"person","name":"WOODHOUSE DAVID J","position":1,"cik":"0001642995","reported_name":"WOODHOUSE DAVID J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-04-08T20:14:24.000Z","date":"2024-04-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":450000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. (\"Parent\") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent (\"Purchaser\"), dated as of February 25, 2024 (\"Merger Agreement\"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the \"Effective Time\"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the \"Offer Price\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an \"In-the-Money Option\") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. (\"Parent\") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent (\"Purchaser\"), dated as of February 25, 2024 (\"Merger Agreement\"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the \"Effective Time\"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the \"Offer Price\")."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an \"In-the-Money Option\") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an \"In-the-Money Option\") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration."}],"balance_after":0,"derivative":{"exercise_price":0.84,"expiration_date":"2031-03-16","underlying":"Common Stock","underlying_shares":450000},"source":{"system":"sec-edgar","filing":"0000950170-24-042609","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1642995/000095017024042609/ownership.xml","form_type":"4"}},{"id":1545625,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":47341,"kind":"person","name":"WOODHOUSE DAVID J","position":1,"cik":"0001642995","reported_name":"WOODHOUSE DAVID J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-04-08T20:14:24.000Z","date":"2024-04-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":400000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. (\"Parent\") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent (\"Purchaser\"), dated as of February 25, 2024 (\"Merger Agreement\"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the \"Effective Time\"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the \"Offer Price\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an \"In-the-Money Option\") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. (\"Parent\") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent (\"Purchaser\"), dated as of February 25, 2024 (\"Merger Agreement\"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the \"Effective Time\"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the \"Offer Price\")."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an \"In-the-Money Option\") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an \"In-the-Money Option\") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration."}],"balance_after":0,"derivative":{"exercise_price":0.84,"expiration_date":"2030-02-03","underlying":"Common Stock","underlying_shares":400000},"source":{"system":"sec-edgar","filing":"0000950170-24-042609","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1642995/000095017024042609/ownership.xml","form_type":"4"}},{"id":1545624,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":47341,"kind":"person","name":"WOODHOUSE DAVID J","position":1,"cik":"0001642995","reported_name":"WOODHOUSE DAVID J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-04-08T20:14:24.000Z","date":"2024-04-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":200000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. (\"Parent\") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent (\"Purchaser\"), dated as of February 25, 2024 (\"Merger Agreement\"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the \"Effective Time\"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the \"Offer Price\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an \"In-the-Money Option\") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. (\"Parent\") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent (\"Purchaser\"), dated as of February 25, 2024 (\"Merger Agreement\"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the \"Effective Time\"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the \"Offer Price\")."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an \"In-the-Money Option\") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an \"In-the-Money Option\") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration."}],"balance_after":0,"derivative":{"exercise_price":0.84,"expiration_date":"2029-02-06","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0000950170-24-042609","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1642995/000095017024042609/ownership.xml","form_type":"4"}},{"id":1545623,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":47341,"kind":"person","name":"WOODHOUSE DAVID J","position":1,"cik":"0001642995","reported_name":"WOODHOUSE DAVID J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-04-08T20:14:24.000Z","date":"2024-04-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":500000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. (\"Parent\") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent (\"Purchaser\"), dated as of February 25, 2024 (\"Merger Agreement\"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the \"Effective Time\"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the \"Offer Price\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an \"In-the-Money Option\") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. (\"Parent\") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent (\"Purchaser\"), dated as of February 25, 2024 (\"Merger Agreement\"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the \"Effective Time\"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the \"Offer Price\")."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an \"In-the-Money Option\") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an \"In-the-Money Option\") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration."}],"balance_after":0,"derivative":{"exercise_price":0.84,"expiration_date":"2028-07-24","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0000950170-24-042609","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1642995/000095017024042609/ownership.xml","form_type":"4"}},{"id":1545622,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":47341,"kind":"person","name":"WOODHOUSE DAVID J","position":1,"cik":"0001642995","reported_name":"WOODHOUSE DAVID J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-04-08T20:14:24.000Z","date":"2024-04-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":57833,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. (\"Parent\") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent (\"Purchaser\"), dated as of February 25, 2024 (\"Merger Agreement\"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the \"Effective Time\"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the \"Offer Price\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an \"In-the-Money Option\") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. (\"Parent\") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent (\"Purchaser\"), dated as of February 25, 2024 (\"Merger Agreement\"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the \"Effective Time\"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the \"Offer Price\")."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an \"In-the-Money Option\") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an \"In-the-Money Option\") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration."}],"balance_after":0,"derivative":{"exercise_price":0.84,"expiration_date":"2028-01-30","underlying":"Common Stock","underlying_shares":57833},"source":{"system":"sec-edgar","filing":"0000950170-24-042609","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1642995/000095017024042609/ownership.xml","form_type":"4"}},{"id":1545621,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":47341,"kind":"person","name":"WOODHOUSE DAVID J","position":1,"cik":"0001642995","reported_name":"WOODHOUSE DAVID J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-04-08T20:14:24.000Z","date":"2024-04-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":87013,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. (\"Parent\") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent (\"Purchaser\"), dated as of February 25, 2024 (\"Merger Agreement\"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the \"Effective Time\"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the \"Offer Price\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an \"In-the-Money Option\") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. (\"Parent\") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent (\"Purchaser\"), dated as of February 25, 2024 (\"Merger Agreement\"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the \"Effective Time\"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the \"Offer Price\")."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an \"In-the-Money Option\") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an \"In-the-Money Option\") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration."}],"balance_after":0,"derivative":{"exercise_price":0.84,"expiration_date":"2027-01-19","underlying":"Common Stock","underlying_shares":87013},"source":{"system":"sec-edgar","filing":"0000950170-24-042609","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1642995/000095017024042609/ownership.xml","form_type":"4"}},{"id":1545620,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":47341,"kind":"person","name":"WOODHOUSE DAVID J","position":1,"cik":"0001642995","reported_name":"WOODHOUSE DAVID J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-04-08T20:14:24.000Z","date":"2024-04-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":255000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. (\"Parent\") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent (\"Purchaser\"), dated as of February 25, 2024 (\"Merger Agreement\"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the \"Effective Time\"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the \"Offer Price\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an \"In-the-Money Option\") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. (\"Parent\") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent (\"Purchaser\"), dated as of February 25, 2024 (\"Merger Agreement\"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the \"Effective Time\"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the \"Offer Price\")."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an \"In-the-Money Option\") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an \"In-the-Money Option\") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration."}],"balance_after":0,"derivative":{"exercise_price":0.84,"expiration_date":"2025-04-21","underlying":"Common Stock","underlying_shares":255000},"source":{"system":"sec-edgar","filing":"0000950170-24-042609","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1642995/000095017024042609/ownership.xml","form_type":"4"}},{"id":1545619,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":47341,"kind":"person","name":"WOODHOUSE DAVID J","position":1,"cik":"0001642995","reported_name":"WOODHOUSE DAVID J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Unit","published_at":"2024-04-08T20:14:24.000Z","date":"2024-04-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":95400,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. (\"Parent\") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent (\"Purchaser\"), dated as of February 25, 2024 (\"Merger Agreement\"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the \"Effective Time\"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the \"Offer Price\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each Restricted Stock Unit represents a contingent right to receive one share of Common Stock. Pursuant to the Merger Agreement, as of the Effective Time, each outstanding Restricted Stock Unit was canceled and the holder of such canceled Restricted Stock Unit was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the Offer Price."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. (\"Parent\") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent (\"Purchaser\"), dated as of February 25, 2024 (\"Merger Agreement\"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the \"Effective Time\"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the \"Offer Price\")."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each Restricted Stock Unit represents a contingent right to receive one share of Common Stock. Pursuant to the Merger Agreement, as of the Effective Time, each outstanding Restricted Stock Unit was canceled and the holder of such canceled Restricted Stock Unit was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the Offer Price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each Restricted Stock Unit represents a contingent right to receive one share of Common Stock. Pursuant to the Merger Agreement, as of the Effective Time, each outstanding Restricted Stock Unit was canceled and the holder of such canceled Restricted Stock Unit was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the Offer Price."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Restricted Stock Units do not have an expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":95400},"source":{"system":"sec-edgar","filing":"0000950170-24-042609","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1642995/000095017024042609/ownership.xml","form_type":"4"}},{"id":1545618,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":47341,"kind":"person","name":"WOODHOUSE DAVID J","position":1,"cik":"0001642995","reported_name":"WOODHOUSE DAVID J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-04-08T20:14:24.000Z","date":"2024-04-05","kind":"other","planned":false,"acquired":false,"shares":97654,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Shares held by The Woodhouse Family Trust 9/8/05."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Disposed of pursuant to a Rollover Agreement between, inter alia, Dr. Woodhouse, Parent and Purchaser, in exchange for shares in Parent."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held by The Woodhouse Family Trust 9/8/05."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-24-042609","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1642995/000095017024042609/ownership.xml","form_type":"4"}},{"id":1545617,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":47341,"kind":"person","name":"WOODHOUSE DAVID J","position":1,"cik":"0001642995","reported_name":"WOODHOUSE DAVID J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-04-08T20:14:24.000Z","date":"2024-04-05","kind":"other","planned":false,"acquired":false,"shares":23993,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. (\"Parent\") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent (\"Purchaser\"), dated as of February 25, 2024 (\"Merger Agreement\"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the \"Effective Time\"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the \"Offer Price\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-24-042609","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1642995/000095017024042609/ownership.xml","form_type":"4"}},{"id":1676381,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":47341,"kind":"person","name":"WOODHOUSE DAVID J","position":1,"cik":"0001642995","reported_name":"WOODHOUSE DAVID J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2024-01-18T23:01:27.000Z","date":"2024-01-16","kind":"tax_withholding","planned":false,"acquired":false,"shares":13032,"price":1.34,"value":17462.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares withheld by the issuer to satisfy the tax obligation realized in connection with the vesting of restricted stock units previously reported in Table 1."}],"balance_after":131822,"source":{"system":"sec-edgar","filing":"0001415889-24-001541","document":"form4-01182024_110120.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1642995/000141588924001541/form4-01182024_110120.xml","form_type":"4"}},{"id":1746754,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":47341,"kind":"person","name":"WOODHOUSE DAVID J","position":1,"cik":"0001642995","reported_name":"WOODHOUSE DAVID J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-11-08T23:09:09.000Z","date":"2023-11-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":500000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Effective November 6, 2023, the Compensation Committee of the Board of Directors of NGM Biopharmaceuticals, Inc. (the \"Company\") approved a stock option repricing which resulted in, for purposes of Section 16 of the Exchange Act, the cancellation of a previously-granted stock option in exchange for a new stock option having a lower exercise price of $0.84 per share, which is the closing price of the Company's common stock on November 6, 2023. The reduced exercise price is subject to the relevant retention period and other terms outlined in the applicable stock option repricing notice. All of the other terms of the stock option remained unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares subject to the stock option vest over a four-year period commencing January 1, 2022, with 1/48th of the shares vesting on a monthly basis."}],"balance_after":0,"derivative":{"exercise_price":15.2,"expiration_date":"2032-03-02","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0001209191-23-054733","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1642995/000120919123054733/doc4.xml","form_type":"4"}},{"id":1746753,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":47341,"kind":"person","name":"WOODHOUSE DAVID J","position":1,"cik":"0001642995","reported_name":"WOODHOUSE DAVID J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-11-08T23:09:09.000Z","date":"2023-11-06","kind":"grant","planned":false,"acquired":true,"shares":500000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Effective November 6, 2023, the Compensation Committee of the Board of Directors of NGM Biopharmaceuticals, Inc. (the \"Company\") approved a stock option repricing which resulted in, for purposes of Section 16 of the Exchange Act, the cancellation of a previously-granted stock option in exchange for a new stock option having a lower exercise price of $0.84 per share, which is the closing price of the Company's common stock on November 6, 2023. The reduced exercise price is subject to the relevant retention period and other terms outlined in the applicable stock option repricing notice. All of the other terms of the stock option remained unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares subject to the stock option vest over a four-year period commencing January 1, 2022, with 1/48th of the shares vesting on a monthly basis."}],"balance_after":500000,"derivative":{"exercise_price":0.84,"expiration_date":"2032-03-02","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0001209191-23-054733","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1642995/000120919123054733/doc4.xml","form_type":"4"}},{"id":1746752,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":47341,"kind":"person","name":"WOODHOUSE DAVID J","position":1,"cik":"0001642995","reported_name":"WOODHOUSE DAVID J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-11-08T23:09:09.000Z","date":"2023-11-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":450000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Effective November 6, 2023, the Compensation Committee of the Board of Directors of NGM Biopharmaceuticals, Inc. (the \"Company\") approved a stock option repricing which resulted in, for purposes of Section 16 of the Exchange Act, the cancellation of a previously-granted stock option in exchange for a new stock option having a lower exercise price of $0.84 per share, which is the closing price of the Company's common stock on November 6, 2023. The reduced exercise price is subject to the relevant retention period and other terms outlined in the applicable stock option repricing notice. All of the other terms of the stock option remained unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to the stock option vest over a four-year period commencing January 1, 2021, with 1/48th of the shares vesting on a monthly basis."}],"balance_after":0,"derivative":{"exercise_price":31.93,"expiration_date":"2031-03-16","underlying":"Common Stock","underlying_shares":450000},"source":{"system":"sec-edgar","filing":"0001209191-23-054733","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1642995/000120919123054733/doc4.xml","form_type":"4"}},{"id":1746751,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":47341,"kind":"person","name":"WOODHOUSE DAVID J","position":1,"cik":"0001642995","reported_name":"WOODHOUSE DAVID J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-11-08T23:09:09.000Z","date":"2023-11-06","kind":"grant","planned":false,"acquired":true,"shares":450000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Effective November 6, 2023, the Compensation Committee of the Board of Directors of NGM Biopharmaceuticals, Inc. (the \"Company\") approved a stock option repricing which resulted in, for purposes of Section 16 of the Exchange Act, the cancellation of a previously-granted stock option in exchange for a new stock option having a lower exercise price of $0.84 per share, which is the closing price of the Company's common stock on November 6, 2023. The reduced exercise price is subject to the relevant retention period and other terms outlined in the applicable stock option repricing notice. All of the other terms of the stock option remained unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to the stock option vest over a four-year period commencing January 1, 2021, with 1/48th of the shares vesting on a monthly basis."}],"balance_after":450000,"derivative":{"exercise_price":0.84,"expiration_date":"2031-03-16","underlying":"Common Stock","underlying_shares":450000},"source":{"system":"sec-edgar","filing":"0001209191-23-054733","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1642995/000120919123054733/doc4.xml","form_type":"4"}},{"id":1746750,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":47341,"kind":"person","name":"WOODHOUSE DAVID J","position":1,"cik":"0001642995","reported_name":"WOODHOUSE DAVID J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-11-08T23:09:09.000Z","date":"2023-11-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":400000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Effective November 6, 2023, the Compensation Committee of the Board of Directors of NGM Biopharmaceuticals, Inc. (the \"Company\") approved a stock option repricing which resulted in, for purposes of Section 16 of the Exchange Act, the cancellation of a previously-granted stock option in exchange for a new stock option having a lower exercise price of $0.84 per share, which is the closing price of the Company's common stock on November 6, 2023. The reduced exercise price is subject to the relevant retention period and other terms outlined in the applicable stock option repricing notice. All of the other terms of the stock option remained unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to the stock option vest over a four-year period commencing January 1, 2020, with 1/48th of the shares vesting on a monthly basis."}],"balance_after":0,"derivative":{"exercise_price":16.47,"expiration_date":"2030-02-03","underlying":"Common Stock","underlying_shares":400000},"source":{"system":"sec-edgar","filing":"0001209191-23-054733","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1642995/000120919123054733/doc4.xml","form_type":"4"}},{"id":1746749,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":47341,"kind":"person","name":"WOODHOUSE DAVID J","position":1,"cik":"0001642995","reported_name":"WOODHOUSE DAVID J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-11-08T23:09:09.000Z","date":"2023-11-06","kind":"grant","planned":false,"acquired":true,"shares":400000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Effective November 6, 2023, the Compensation Committee of the Board of Directors of NGM Biopharmaceuticals, Inc. (the \"Company\") approved a stock option repricing which resulted in, for purposes of Section 16 of the Exchange Act, the cancellation of a previously-granted stock option in exchange for a new stock option having a lower exercise price of $0.84 per share, which is the closing price of the Company's common stock on November 6, 2023. The reduced exercise price is subject to the relevant retention period and other terms outlined in the applicable stock option repricing notice. All of the other terms of the stock option remained unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to the stock option vest over a four-year period commencing January 1, 2020, with 1/48th of the shares vesting on a monthly basis."}],"balance_after":400000,"derivative":{"exercise_price":0.84,"expiration_date":"2030-02-03","underlying":"Common Stock","underlying_shares":400000},"source":{"system":"sec-edgar","filing":"0001209191-23-054733","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1642995/000120919123054733/doc4.xml","form_type":"4"}},{"id":1746748,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":47341,"kind":"person","name":"WOODHOUSE DAVID J","position":1,"cik":"0001642995","reported_name":"WOODHOUSE DAVID J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-11-08T23:09:09.000Z","date":"2023-11-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":200000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Effective November 6, 2023, the Compensation Committee of the Board of Directors of NGM Biopharmaceuticals, Inc. (the \"Company\") approved a stock option repricing which resulted in, for purposes of Section 16 of the Exchange Act, the cancellation of a previously-granted stock option in exchange for a new stock option having a lower exercise price of $0.84 per share, which is the closing price of the Company's common stock on November 6, 2023. The reduced exercise price is subject to the relevant retention period and other terms outlined in the applicable stock option repricing notice. All of the other terms of the stock option remained unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Fully vested."}],"balance_after":0,"derivative":{"exercise_price":12.06,"expiration_date":"2029-02-06","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001209191-23-054733","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1642995/000120919123054733/doc4.xml","form_type":"4"}},{"id":1746747,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":47341,"kind":"person","name":"WOODHOUSE DAVID J","position":1,"cik":"0001642995","reported_name":"WOODHOUSE DAVID J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-11-08T23:09:09.000Z","date":"2023-11-06","kind":"grant","planned":false,"acquired":true,"shares":200000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Effective November 6, 2023, the Compensation Committee of the Board of Directors of NGM Biopharmaceuticals, Inc. (the \"Company\") approved a stock option repricing which resulted in, for purposes of Section 16 of the Exchange Act, the cancellation of a previously-granted stock option in exchange for a new stock option having a lower exercise price of $0.84 per share, which is the closing price of the Company's common stock on November 6, 2023. The reduced exercise price is subject to the relevant retention period and other terms outlined in the applicable stock option repricing notice. All of the other terms of the stock option remained unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Fully vested."}],"balance_after":200000,"derivative":{"exercise_price":0.84,"expiration_date":"2029-02-06","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001209191-23-054733","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1642995/000120919123054733/doc4.xml","form_type":"4"}},{"id":1746746,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":47341,"kind":"person","name":"WOODHOUSE DAVID J","position":1,"cik":"0001642995","reported_name":"WOODHOUSE DAVID J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-11-08T23:09:09.000Z","date":"2023-11-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":500000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Effective November 6, 2023, the Compensation Committee of the Board of Directors of NGM Biopharmaceuticals, Inc. (the \"Company\") approved a stock option repricing which resulted in, for purposes of Section 16 of the Exchange Act, the cancellation of a previously-granted stock option in exchange for a new stock option having a lower exercise price of $0.84 per share, which is the closing price of the Company's common stock on November 6, 2023. The reduced exercise price is subject to the relevant retention period and other terms outlined in the applicable stock option repricing notice. All of the other terms of the stock option remained unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Fully vested."}],"balance_after":0,"derivative":{"exercise_price":11,"expiration_date":"2028-07-24","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0001209191-23-054733","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1642995/000120919123054733/doc4.xml","form_type":"4"}},{"id":1746745,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":47341,"kind":"person","name":"WOODHOUSE DAVID J","position":1,"cik":"0001642995","reported_name":"WOODHOUSE DAVID J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-11-08T23:09:09.000Z","date":"2023-11-06","kind":"grant","planned":false,"acquired":true,"shares":500000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Effective November 6, 2023, the Compensation Committee of the Board of Directors of NGM Biopharmaceuticals, Inc. (the \"Company\") approved a stock option repricing which resulted in, for purposes of Section 16 of the Exchange Act, the cancellation of a previously-granted stock option in exchange for a new stock option having a lower exercise price of $0.84 per share, which is the closing price of the Company's common stock on November 6, 2023. The reduced exercise price is subject to the relevant retention period and other terms outlined in the applicable stock option repricing notice. All of the other terms of the stock option remained unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Fully vested."}],"balance_after":500000,"derivative":{"exercise_price":0.84,"expiration_date":"2028-07-24","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0001209191-23-054733","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1642995/000120919123054733/doc4.xml","form_type":"4"}},{"id":1746744,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":47341,"kind":"person","name":"WOODHOUSE DAVID J","position":1,"cik":"0001642995","reported_name":"WOODHOUSE DAVID J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-11-08T23:09:09.000Z","date":"2023-11-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":57833,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Effective November 6, 2023, the Compensation Committee of the Board of Directors of NGM Biopharmaceuticals, Inc. (the \"Company\") approved a stock option repricing which resulted in, for purposes of Section 16 of the Exchange Act, the cancellation of a previously-granted stock option in exchange for a new stock option having a lower exercise price of $0.84 per share, which is the closing price of the Company's common stock on November 6, 2023. The reduced exercise price is subject to the relevant retention period and other terms outlined in the applicable stock option repricing notice. All of the other terms of the stock option remained unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Fully vested."}],"balance_after":0,"derivative":{"exercise_price":8.14,"expiration_date":"2028-01-30","underlying":"Common Stock","underlying_shares":57833},"source":{"system":"sec-edgar","filing":"0001209191-23-054733","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1642995/000120919123054733/doc4.xml","form_type":"4"}},{"id":1746743,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":47341,"kind":"person","name":"WOODHOUSE DAVID J","position":1,"cik":"0001642995","reported_name":"WOODHOUSE DAVID J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-11-08T23:09:09.000Z","date":"2023-11-06","kind":"grant","planned":false,"acquired":true,"shares":57833,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Effective November 6, 2023, the Compensation Committee of the Board of Directors of NGM Biopharmaceuticals, Inc. (the \"Company\") approved a stock option repricing which resulted in, for purposes of Section 16 of the Exchange Act, the cancellation of a previously-granted stock option in exchange for a new stock option having a lower exercise price of $0.84 per share, which is the closing price of the Company's common stock on November 6, 2023. The reduced exercise price is subject to the relevant retention period and other terms outlined in the applicable stock option repricing notice. All of the other terms of the stock option remained unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Fully vested."}],"balance_after":57833,"derivative":{"exercise_price":0.84,"expiration_date":"2028-01-30","underlying":"Common Stock","underlying_shares":57833},"source":{"system":"sec-edgar","filing":"0001209191-23-054733","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1642995/000120919123054733/doc4.xml","form_type":"4"}},{"id":1746742,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":47341,"kind":"person","name":"WOODHOUSE DAVID J","position":1,"cik":"0001642995","reported_name":"WOODHOUSE DAVID J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-11-08T23:09:09.000Z","date":"2023-11-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":87013,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Effective November 6, 2023, the Compensation Committee of the Board of Directors of NGM Biopharmaceuticals, Inc. (the \"Company\") approved a stock option repricing which resulted in, for purposes of Section 16 of the Exchange Act, the cancellation of a previously-granted stock option in exchange for a new stock option having a lower exercise price of $0.84 per share, which is the closing price of the Company's common stock on November 6, 2023. The reduced exercise price is subject to the relevant retention period and other terms outlined in the applicable stock option repricing notice. All of the other terms of the stock option remained unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Fully vested."}],"balance_after":0,"derivative":{"exercise_price":7.7,"expiration_date":"2027-01-19","underlying":"Common Stock","underlying_shares":87013},"source":{"system":"sec-edgar","filing":"0001209191-23-054733","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1642995/000120919123054733/doc4.xml","form_type":"4"}},{"id":1746741,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":47341,"kind":"person","name":"WOODHOUSE DAVID J","position":1,"cik":"0001642995","reported_name":"WOODHOUSE DAVID J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-11-08T23:09:09.000Z","date":"2023-11-06","kind":"grant","planned":false,"acquired":true,"shares":87013,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Effective November 6, 2023, the Compensation Committee of the Board of Directors of NGM Biopharmaceuticals, Inc. (the \"Company\") approved a stock option repricing which resulted in, for purposes of Section 16 of the Exchange Act, the cancellation of a previously-granted stock option in exchange for a new stock option having a lower exercise price of $0.84 per share, which is the closing price of the Company's common stock on November 6, 2023. The reduced exercise price is subject to the relevant retention period and other terms outlined in the applicable stock option repricing notice. All of the other terms of the stock option remained unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Fully vested."}],"balance_after":87013,"derivative":{"exercise_price":0.84,"expiration_date":"2027-01-19","underlying":"Common Stock","underlying_shares":87013},"source":{"system":"sec-edgar","filing":"0001209191-23-054733","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1642995/000120919123054733/doc4.xml","form_type":"4"}},{"id":1746740,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":47341,"kind":"person","name":"WOODHOUSE DAVID J","position":1,"cik":"0001642995","reported_name":"WOODHOUSE DAVID J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-11-08T23:09:09.000Z","date":"2023-11-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":255000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Effective November 6, 2023, the Compensation Committee of the Board of Directors of NGM Biopharmaceuticals, Inc. (the \"Company\") approved a stock option repricing which resulted in, for purposes of Section 16 of the Exchange Act, the cancellation of a previously-granted stock option in exchange for a new stock option having a lower exercise price of $0.84 per share, which is the closing price of the Company's common stock on November 6, 2023. The reduced exercise price is subject to the relevant retention period and other terms outlined in the applicable stock option repricing notice. All of the other terms of the stock option remained unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Fully vested."}],"balance_after":0,"derivative":{"exercise_price":7.54,"expiration_date":"2025-04-21","underlying":"Common Stock","underlying_shares":255000},"source":{"system":"sec-edgar","filing":"0001209191-23-054733","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1642995/000120919123054733/doc4.xml","form_type":"4"}},{"id":1746739,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":47341,"kind":"person","name":"WOODHOUSE DAVID J","position":1,"cik":"0001642995","reported_name":"WOODHOUSE DAVID J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-11-08T23:09:09.000Z","date":"2023-11-06","kind":"grant","planned":false,"acquired":true,"shares":255000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Effective November 6, 2023, the Compensation Committee of the Board of Directors of NGM Biopharmaceuticals, Inc. (the \"Company\") approved a stock option repricing which resulted in, for purposes of Section 16 of the Exchange Act, the cancellation of a previously-granted stock option in exchange for a new stock option having a lower exercise price of $0.84 per share, which is the closing price of the Company's common stock on November 6, 2023. The reduced exercise price is subject to the relevant retention period and other terms outlined in the applicable stock option repricing notice. All of the other terms of the stock option remained unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Fully vested."}],"balance_after":255000,"derivative":{"exercise_price":0.84,"expiration_date":"2025-04-21","underlying":"Common Stock","underlying_shares":255000},"source":{"system":"sec-edgar","filing":"0001209191-23-054733","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1642995/000120919123054733/doc4.xml","form_type":"4"}},{"id":1884587,"issuer":{"id":6092,"kind":"organization","name":"Surrozen, Inc./DE"},"owners":[{"id":47341,"kind":"person","name":"WOODHOUSE DAVID J","position":1,"cik":"0001642995","reported_name":"WOODHOUSE DAVID J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2023-05-19T20:18:19.000Z","date":"2023-05-18","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":20000,"derivative":{"exercise_price":0.56,"exercise_date":"2023-06-18","expiration_date":"2033-05-18","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001593968-23-000843","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1642995/000159396823000843/primary_01.xml","form_type":"4"}},{"id":1969082,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":47341,"kind":"person","name":"WOODHOUSE DAVID J","position":1,"cik":"0001642995","reported_name":"WOODHOUSE DAVID J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-06T22:09:32.000Z","date":"2023-03-02","kind":"grant","acquired":true,"shares":500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"1/2 of the shares subject to the stock option vest on the first anniversary of the grant date of March 2, 2023 (the \"2023 Grant Date\"), and the remaining 1/2 of the shares vest on the second anniversary of the 2023 Grant Date."}],"balance_after":500000,"derivative":{"exercise_price":4.36,"expiration_date":"2033-03-01","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0001209191-23-016396","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1642995/000120919123016396/doc4.xml","form_type":"4"}},{"id":1969081,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":47341,"kind":"person","name":"WOODHOUSE DAVID J","position":1,"cik":"0001642995","reported_name":"WOODHOUSE DAVID J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-06T22:09:32.000Z","date":"2023-03-02","kind":"grant","acquired":true,"shares":381600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to the stock option vest over a four-year period commencing January 1, 2023, with 1/48th of the shares vesting on a monthly basis."}],"balance_after":381600,"derivative":{"exercise_price":4.36,"expiration_date":"2033-03-01","underlying":"Common Stock","underlying_shares":381600},"source":{"system":"sec-edgar","filing":"0001209191-23-016396","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1642995/000120919123016396/doc4.xml","form_type":"4"}},{"id":1969080,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":47341,"kind":"person","name":"WOODHOUSE DAVID J","position":1,"cik":"0001642995","reported_name":"WOODHOUSE DAVID J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-03-06T22:09:32.000Z","date":"2023-03-02","kind":"grant","acquired":true,"shares":127200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock issuable upon the vesting and settlement of restricted stock units (\"RSUs\"). 1/4th of the RSUs vest on each of January 15, 2024, January 15, 2025, January 15, 2026 and January 15, 2027."}],"balance_after":144854,"source":{"system":"sec-edgar","filing":"0001209191-23-016396","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1642995/000120919123016396/doc4.xml","form_type":"4"}},{"id":2237760,"issuer":{"id":6092,"kind":"organization","name":"Surrozen, Inc./DE"},"owners":[{"id":47341,"kind":"person","name":"WOODHOUSE DAVID J","position":1,"cik":"0001642995","reported_name":"WOODHOUSE DAVID J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2022-06-09T21:51:43.000Z","date":"2022-06-07","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options fully vest and become exercisable on the one-year anniversary of the grant date, subject to the reporting person's continuous service as a director."}],"balance_after":20000,"derivative":{"exercise_price":2.79,"exercise_date":"2023-06-07","expiration_date":"2032-06-07","underlying":"Surrozen, Inc. Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001593968-22-001111","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1642995/000159396822001111/primary_01.xml","form_type":"4"}},{"id":2350320,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":47341,"kind":"person","name":"WOODHOUSE DAVID J","position":1,"cik":"0001642995","reported_name":"WOODHOUSE DAVID J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-04T21:06:50.000Z","date":"2022-03-03","kind":"grant","acquired":true,"shares":500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the stock option vest over a four-year period commencing January 1, 2022, with 1/48th of the shares vesting on a monthly basis."}],"balance_after":500000,"derivative":{"exercise_price":15.2,"expiration_date":"2032-03-02","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0001209191-22-016192","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1642995/000120919122016192/doc4.xml","form_type":"4"}},{"id":2456179,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":47341,"kind":"person","name":"WOODHOUSE DAVID J","position":1,"cik":"0001642995","reported_name":"WOODHOUSE DAVID J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-12-30T22:09:25.000Z","date":"2021-12-29","kind":"exercise","acquired":false,"shares":4667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to the stock option are early exercisable and vest over a four-year period commencing January 1, 2018, with 1/48th of the shares vesting on a monthly basis."}],"balance_after":57833,"derivative":{"exercise_price":8.14,"expiration_date":"2028-01-30","underlying":"Common Stock","underlying_shares":4667},"source":{"system":"sec-edgar","filing":"0001209191-21-071613","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1642995/000120919121071613/doc4.xml","form_type":"4"}},{"id":2456178,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":47341,"kind":"person","name":"WOODHOUSE DAVID J","position":1,"cik":"0001642995","reported_name":"WOODHOUSE DAVID J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-12-30T22:09:25.000Z","date":"2021-12-29","kind":"exercise","acquired":false,"shares":12987,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Fully vested."}],"balance_after":87013,"derivative":{"exercise_price":7.7,"expiration_date":"2027-01-19","underlying":"Common Stock","underlying_shares":12987},"source":{"system":"sec-edgar","filing":"0001209191-21-071613","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1642995/000120919121071613/doc4.xml","form_type":"4"}},{"id":2456177,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":47341,"kind":"person","name":"WOODHOUSE DAVID J","position":1,"cik":"0001642995","reported_name":"WOODHOUSE DAVID J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-12-30T22:09:25.000Z","date":"2021-12-29","kind":"exercise","acquired":true,"shares":4667,"price":8.14,"value":37989.38,"ownership":{"direct":true},"balance_after":17654,"source":{"system":"sec-edgar","filing":"0001209191-21-071613","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1642995/000120919121071613/doc4.xml","form_type":"4"}},{"id":2456176,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":47341,"kind":"person","name":"WOODHOUSE DAVID J","position":1,"cik":"0001642995","reported_name":"WOODHOUSE DAVID J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-12-30T22:09:25.000Z","date":"2021-12-29","kind":"exercise","acquired":true,"shares":12987,"price":7.7,"value":99999.9,"ownership":{"direct":true},"balance_after":12987,"source":{"system":"sec-edgar","filing":"0001209191-21-071613","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1642995/000120919121071613/doc4.xml","form_type":"4"}},{"id":2502867,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":47341,"kind":"person","name":"WOODHOUSE DAVID J","position":1,"cik":"0001642995","reported_name":"WOODHOUSE DAVID J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-11-20T00:39:08.000Z","date":"2021-11-18","kind":"exercise","acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Fully vested."}],"balance_after":255000,"derivative":{"exercise_price":7.54,"expiration_date":"2025-04-21","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-21-065973","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1642995/000120919121065973/doc4.xml","form_type":"4"}},{"id":2502866,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":47341,"kind":"person","name":"WOODHOUSE DAVID J","position":1,"cik":"0001642995","reported_name":"WOODHOUSE DAVID J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-11-20T00:39:08.000Z","date":"2021-11-18","kind":"sale","acquired":false,"shares":15000,"price":20.02,"value":300300.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 18, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.07. The reporting person has provided to the issuer, and undertakes to provide to the staff of the Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-21-065973","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1642995/000120919121065973/doc4.xml","form_type":"4"}},{"id":2502865,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":47341,"kind":"person","name":"WOODHOUSE DAVID J","position":1,"cik":"0001642995","reported_name":"WOODHOUSE DAVID J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-11-20T00:39:08.000Z","date":"2021-11-18","kind":"exercise","acquired":true,"shares":15000,"price":7.54,"value":113100.0,"ownership":{"direct":true},"balance_after":15000,"source":{"system":"sec-edgar","filing":"0001209191-21-065973","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1642995/000120919121065973/doc4.xml","form_type":"4"}},{"id":2779289,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":47341,"kind":"person","name":"WOODHOUSE DAVID J","position":1,"cik":"0001642995","reported_name":"WOODHOUSE DAVID J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-03-19T00:23:40.000Z","date":"2021-03-17","kind":"grant","acquired":true,"shares":450000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the stock option vest over a four-year period commencing January 1, 2021, with 1/48th of the shares vesting on a monthly basis."}],"balance_after":450000,"derivative":{"exercise_price":31.93,"expiration_date":"2031-03-16","underlying":"Common Stock","underlying_shares":450000},"source":{"system":"sec-edgar","filing":"0001209191-21-021931","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1642995/000120919121021931/doc4.xml","form_type":"4"}},{"id":3286629,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":47341,"kind":"person","name":"WOODHOUSE DAVID J","position":1,"cik":"0001642995","reported_name":"WOODHOUSE DAVID J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and acting CFO"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-02-07T01:02:50.000Z","date":"2020-02-04","kind":"grant","acquired":true,"shares":400000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the stock option vest over a four-year period commencing January 1, 2020, with 1/48th of the shares vesting on a monthly basis."}],"balance_after":400000,"derivative":{"exercise_price":16.47,"expiration_date":"2030-02-03","underlying":"Common Stock","underlying_shares":400000},"source":{"system":"sec-edgar","filing":"0001209191-20-007322","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1642995/000120919120007322/doc4.xml","form_type":"4"}}]}